Related Experiment Videos
A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy
H Masumura1, S Kunitada, K Irie
1Department of Pharmacology, Kagawa Medical School, Japan.
Abstract:
Spontaneously hypertensive rats (SHR) were injected with streptozotocin (STZ-SHR) to induce diabetes. The effect of DP-1904, a thromboxane A2 synthetase inhibitor, on diabetic nephropathy was then studied by administering it for 5 months (1 or 10 mg/kg). DP-1904 did not affect renal 6-keto prostaglandin (PG)F1 alpha production in STZ-SHR, but markedly inhibited renal thromboxane (TX) B2 production, so that the 6-keto PGF1 alpha/TXB2 ratio was significantly increased (P less than 0.05). STZ-SHR showed significant uraemia and proteinuria, plus increases in urinary gamma-glutamyl-transpeptidase and urinary N-acetyl-beta-glucosaminidase. DP-1904 significantly decreased (P less than 0.01) the urinary changes. STZ-SHR also showed an increase in mesangial periodic acid-Schiff-positive substance and in relative renal weight, both of which were significantly inhibited by DP-1904 (P less than 0.05). Thus, DP-1904 inhibited both TXB2 production and the progression of renal damage in STZ-SHR.
Insights
DP-1904, a thromboxane A2 synthetase inhibitor, reduced kidney damage in diabetic rats. It lowered thromboxane B2 levels and improved markers of kidney disease, suggesting a therapeutic potential for diabetic nephropathy.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy is a major complication of diabetes mellitus.
- Thromboxane A2 plays a role in the pathogenesis of diabetic kidney disease.
Purpose of the Study:
- To investigate the effect of DP-1904, a thromboxane A2 synthetase inhibitor, on diabetic nephropathy in streptozotocin-induced diabetic spontaneously hypertensive rats (STZ-SHR).
Main Methods:
- STZ-SHR were treated with DP-1904 (1 or 10 mg/kg) for 5 months.
- Renal prostaglandin (PG) and thromboxane (TX) levels were measured.
- Urinary markers of kidney damage (gamma-glutamyl-transpeptidase, N-acetyl-beta-glucosaminidase) and renal histological changes were assessed.
Main Results:
- DP-1904 significantly inhibited renal thromboxane B2 production and increased the 6-keto PGF1 alpha/TXB2 ratio.
- DP-1904 decreased elevated urinary markers of kidney damage in STZ-SHR.
- DP-1904 attenuated increases in mesangial matrix and relative renal weight.
Conclusions:
- DP-1904 effectively inhibits thromboxane production.
- DP-1904 demonstrates renoprotective effects in a rat model of diabetic nephropathy.
- DP-1904 may represent a potential therapeutic agent for managing diabetic kidney disease.